Search

Displaying results 2931 - 2940 of 4234 in total
  1. Drug

    Sea salt

    go.drugbank.com/drugs/DB11266
    Approved

    Sea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.”

  2. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]

  3. Drug

    Trimebutine

    go.drugbank.com/drugs/DB09089
    ApprovedInvestigational

    It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form.

  4. Drug

    Indocyanine green acid form

    go.drugbank.com/drugs/DB09374
    ApprovedInvestigational

    Each vial of Indocyanine Green for Injection USP contains 25 mg of Indocyanine Green as a sterile lyophilized powder with no more than 5% sodium iodide.

  5. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.

  6. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    [L53833] Dordaviprone was initially studied as an anticancer agent that induces TNF-Related Apoptosis-Inducing Ligand (TRAIL).

  7. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.

  8. Drug

    Chelerythrine

    go.drugbank.com/drugs/DB17024
    Experimental

    A benzophenanthridine alkaloid evaluated as a kinase-inhibitor.[A252982]

  9. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

  10. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.